Bayer says FDA panel confirms safety of Aleve

02/24/2005 | iWon

Bayer said the recent judgment by an FDA advisory panel confirms the safety of the company's painkiller Aleve, distinguishing the safety profile of the drug's major ingredient, naproxen, from selective Cox-2 inhibitors and nonselective and nonsteroidal anti-inflammatory drugs. The company also noted an Alzheimer's trial was halted last December because of "administrative and practical" issues and not because of Aleve.

View Full Article in:

iWon

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX